Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis

Breast Cancer Research and Treatment

Volumn 86, Issue 3, 2004, Pages 269-279

  Neville Webbe, H L ^a   Cross, N A ^a   Eaton, C L ^a   Nyambo, R ^a   Evans, C A ^a   Coleman, R E ^a   Holen, I ^a  

^a Depto de Quim Analitica   (Spain)

Author keywords

apoptosis; bone marrow stromal cells; bone metastases; breast cancer; OPG; TRAIL induced apoptosis

Indexed keywords

OSTEOPROTEGERIN; RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BINDING AFFINITY; BONE MARROW CELL; BONE TURNOVER; BREAST CANCER; CANCER CELL; CANCER PATIENT; CELL CULTURE; CELL GROWTH; CELL ISOLATION; CELL PROTECTION; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FAMILY; STROMA CELL; TUMOR CELL;

ANTIGENS, CD95; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BONE MARROW CELLS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL SURVIVAL; FEMALE; GLYCOPROTEINS; HUMANS; LIGANDS; MEMBRANE GLYCOPROTEINS; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; STROMAL CELLS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4043138669     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000036900.48763.b3     Document Type: Article

References (16)

1. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 8: 584-593, 2002
2. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morianga T, Higashio K: Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Comm. 234: 137-142, 1997
3. Simmonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliot R, Colombero A, Tan HL, Trail G, Sullivan J, Davey E, Bucay N, Renshaw-Gregg L, Hughes, TM, Hill D, Pattison W, Campbell P, Boyle WJ: Osteoprotegrin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997
4. Khosla S: The OPG/RANKL/RANK system. Minireview: Endocrinol 142: 5050-5055, 2001
5. Zhang J, Qi Y, Lin D, Smith P, Strayhorn C, Mizokam A, Fu Z, Westman J, Keller ET: Osteoprotegerin inhibits prostate cancer induced osteoclastogenesis and prevents prostate tumour growth in the bone. J. Clin. Investig. 107: 1235-1244, 2001
6. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ: Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 61(11): 4432-4436, 2001
7. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenburg M, Lee JC, Young PR: Osteoprotegrin is a receptor for cytotoxic ligand TRAIL. J. Biol. Chem. 273: 14363-14367, 1998
8. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumour necrosis factor cytokine family. J. Biol. Chem. 271: 12687-12690, 1996
9. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Hideo Yagita H, Okumura K: Critical role for tumour necrosis factor-related apoptosis inducing ligand in immune surveillance against tumour development. J. Exp. Med. 195: 161-169, 2002
10. Sheridan P, Marsters SA, Pitti RM, Gurney A, Skubatch, M, Baldwin D, Ramarkrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A: Control of TRAIL induced apoptosis by a family of signalling and decoy receptors. Science 277: 818-821, 1997
11. Holen I, Croucher PI, Hamdy FC, Eaton CL: Osteoprotegrin is a survival factor for human prostate cancer cells. Cancer Res. 62: 1619-1623, 2002
12. Klingler HC, Bretland AJ, Reid SV, Chapple CR, Eaton CL: Regulation of prostatic stromal cell growth and function by transforming growth factor beta (TGFβ). Prostate 41: 110-120, 1999
13. Shipman CM, Croucher PI: Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63(5): 912-916, 2003
14. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM: Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J. Biol. Chem. 275(28): 20959-20962, 2000
15. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S: Myeloma cells induce imbalance in the osteoprotegerin/ osteoprotegerin ligand system in the human bone marrow environment. Blood 98(13): 3527-3533, 2001
16. Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A: Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100(8): 3002-3007, 2002